论文部分内容阅读
Objective Background and aim: As repetitive transcatheter arterial chemoembolization(TACE)or combined therapy of TACE with Sorafenib has been frequently used in an increasing number of patients with intermediate-stage or advanced-stage hepatocellular carcinoma(HCC),the evaluation of pre-treatment liver function becomes a major concern for the implementation of such combination treatment prone to induce treatment-related liver function impairment and compromise patients prognosis.